Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drugs associated with vasculitis

P A Merkel1

  • 1Arthritis Unit-Bulfinch 165, Massachusetts General Hospital, Boston 02114, USA.

Current Opinion in Rheumatology
|February 4, 1998
PubMed
Summary
This summary is machine-generated.

Certain medications, including hematopoietic growth factors and interferons, can trigger or mimic vasculitis. Antineutrophil cytoplasmic antibody (ANCA) testing has identified drug-induced vasculitis linked to hydralazine, propylthiouracil, penicillamine, and minocycline.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A disease-associated gene desert directs macrophage inflammation through ETS2.

Nature·2024
Same author

Cardiovascular risk factors and incident giant cell arteritis: a population-based cohort study.

Scandinavian journal of rheumatology·2018
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise.

Scandinavian journal of rheumatology·2016
Same author

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Annals of the rheumatic diseases·2016
Same author

Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis.

The British journal of dermatology·2016

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Emerging therapeutic agents are increasingly linked to vasculitis development.
  • Hematopoietic growth factors (e.g., G-CSF, GM-CSF) can induce or mimic conditions like Sweet's syndrome.
  • Interferon therapy is associated with diverse autoimmune phenomena, occasionally manifesting as vasculitis.

Purpose of the Study:

  • To review the association between specific medications and vasculitis.
  • To highlight the role of antineutrophil cytoplasmic antibody (ANCA) testing in diagnosing drug-induced vasculitis.
  • To inform clinicians about potential drug-induced vasculitis.

Main Methods:

  • Literature review of case reports and clinical evidence.
  • Analysis of drug associations with vasculitis and ANCA positivity.

Related Experiment Videos

  • Synthesis of findings on specific agents like G-CSF, GM-CSF, interferons, hydralazine, propylthiouracil, penicillamine, and minocycline.

    • Main Results:

    • Hematopoietic growth factors can cause Sweet's syndrome and pyoderma gangrenosum.
    • Interferons are linked to autoimmune phenomena, including rare cases of vasculitis.
    • Hydralazine and propylthiouracil are frequently associated with ANCA-positive vasculitis.
    • Penicillamine and minocycline are implicated in a smaller number of ANCA-associated vasculitis cases.

    Conclusions:

    • Clinicians must be aware of drugs that can induce vasculitis.
    • Caution is advised when prescribing these agents, especially in patients with pre-existing vasculitis.
    • Increased ANCA testing has expanded the recognition of drug-induced vasculitis.